2 months Dyne Therapeutics (NASDAQ:DYN) Downgraded by JPMorgan Chase & Co. MarketBeat
JPMorgan Chase & Co. lowered Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the company from $43.00 to $35.00 in a research report on Thursday.
JPMorgan (JPM) · Nasdaq 100 · Science
X